Lung Cancer

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung cancer.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients with non-small cell lung cancer.

During my lung cancer journey, I learned a few important ways to help me lessen the apprehension I felt, including meditation.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

As someone who disliked pink for years, it has grown on me over time, especially after having breast cancer.

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and following chemotherapy.

Two patients reflected on how extraordinary their oncology nurses are — even noting that they forget about their cancer when talking with their nurses.

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

Two radiation therapy techniques, SBRT and hypofractionated CRT, may not have many differences for patients with stage 1 NSCLC, but limitations matter.

When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for immunotherapy.

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal metastases in patients with EGFR-variant NSCLC.

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is as effective as in-person care.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.

Two colleagues of Amy Wallace, an oncology nurse, nominated her for the Extraordinary Healer Award based on her care of patients with lung cancer.

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.

Following a CURE® Educated Patient® Lung Cancer Summit, the City of Hope expert answered 10 commonly asked questions from patients with lung cancer.

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

Two vastly different approaches to navigating the cancer journey may or may not be mutually exclusive.

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

The FDA has approved Rybrevant plus chemotherapy in certain patients with locally advanced or metastatic non-small cell lung cancer.

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial.

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.